- Home
- KPTI vs QNCX Comparison
KPTI vs QNCX Comparison
Compare KPTI & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPTI | QNCX |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.7M | 17.5M |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | KPTI | QNCX |
|---|---|---|
| Price | $0.88 | $29.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $7.25 | ★ $75.43 |
| AVG Volume (30 Days) | ★ 1.2M | 14.5K |
| Earning Date | 11-02-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $146,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.20 | $0.08 |
| 52 Week High | $10.99 | $35.41 |
Technical Indicators
Market Signals| Indicator | KPTI | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 23.57 | 57.40 |
| Support Level | N/A | $29.95 |
| Resistance Level | $2.16 | $34.58 |
| Average True Range (ATR) | 0.16 | 2.35 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 0.00 | 86.14 |
Price Performance
Historical ComparisonAbout KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.